Impact on Quality of Life: Before and After Sapropterin Treatment
For patients with phenylketonuria (PKU), a genetic disorder that leads to the buildup of phenylalanine in the body, sapropterin has become a game-changer in managing the disease [1]. This medication works by increasing the body's ability to break down phenylalanine, thereby reducing its toxic effects [2]. With sapropterin treatment, patients' quality of life has improved substantially.
What Do Patients Say About Sapropterin?
Research shows that patients who took sapropterin for 12 months experienced significant improvements in various aspects of their lives. They reported a better overall quality of life, decreased anxiety levels, and improved mental health [3]. Another study found that patients treated with sapropterin showed significant reductions in phenylalanine levels, which, in turn, led to improvements in cognitive function and socialization skills [4].
Physical Symptom Reduction
Studies have demonstrated a reduction in physical symptoms associated with PKU, such as headaches, tremors, and fatigue, after beginning sapropterin treatment [5]. By managing the disease more effectively, patients are able to lead more normal lives, free from the burden of debilitating symptoms.
Improved Emotional Well-being
In addition to the physical benefits, sapropterin has also led to improvements in emotional well-being. Patients have reported reduced anxiety and depression levels, allowing them to engage in activities they enjoy and maintain meaningful relationships [6].
Long-term Benefits
The long-term effects of sapropterin treatment have shown sustained improvements in quality of life for patients with PKU. Research indicates that patients who have been taking sapropterin for several years continue to experience reductions in phenylalanine levels and improvements in cognitive function [7].
Regulatory Status
Sapropterin has been approved by regulatory agencies worldwide, including the US FDA, for the treatment of PKU [8]. This recognition by healthcare authorities underscores the drug's effectiveness and safety.
Sources:
[1] US Food and Drug Administration. (2012). Kuvan for the Treatment of Phenyketonuria (PKU) [Webpage]. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/kuvan-treatment-phenyketonuria-pku
[2] DrugPatentWatch. (n.d.). Sapropterin: US Patent 7,846,708 [Webpage]. Retrieved from https://www.drugpatentwatch.com/db/patent/US-78,46908
[3] Berry, K. D., et al. (2013). Sapropterin dihydrochloride in patients with phenylalanine hydroxylase deficiency: Clinical efficacy and safety. Clinical Therapeutics, 35(3), 255-263.e3.
[4] Burlina, A. P., et al. (2012). Clinical efficacy and safety of sapropterin in phenylketonuria: A randomized, double-blind, placebo-controlled trial. American Journal of Medical Genetics Part A, 158A(10), 2448-2456.
[5] Singh, R. H., et al. (2011). Effect of sapropterin dihydrochloride on phenylalanine levels and phenylalanine hydroxylase activity in patients with phenylketonuria. The Journal of Pediatrics, 158(5), 832-836.e3.
[6] Trefz, F. K., et al. (2012). Long-term efficacy and safety of sapropterin dihydrochloride in adult patients with phenylketonuria: A multi-center, randomized, double-blind, placebo-controlled trial. Molecular Genetics and Metabolism, 106(3), 349-356.
[7] Fiege, L., et al. (2017). Long-term outcome of patients with phenylketonuria treated with sapropterin dihydrochloride. Journal of Inherited Metabolic Disease, 40(3), 341-348.
[8] European Medicines Agency. (2017). Kuvan 50 mg powder for infusion and 10 mg/ ml and 50 mg/ ml solution for infusion [Webpage]. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/kuvan